Time for Investors to Take the Plunge on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Equity Research firms currently have a positive stance on shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). The majority of analysts covering the equity have either a Buy or Strong Buy recommendation on the stock, yielding a consensus score of 2.30. This is based on the research brokerage reports taken into consideration by Thomson Reuters. Those same analysts are projecting that the stock will reach $467.86 on a short term basis.

At the time of writing, the stock was trading at $394.99. This represents a change from the opening price of -2.19%. In terms of performance, year to date, the stock is -25.80%. The monthly stock performance comes in at 2.39%. For the quarter, shares are performing at 12.02%. Weekly performance analysis shows the equity at -0.32%.

In taking a look at technical levels, shares are trading -3.49% away from the 50 day simple moving average and -2.80% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -33.35% away from it’s 52- week high and 20.02% away from its 52 week low. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. As of writing, Regeneron Pharmaceuticals, Inc.’s RSI stands at 42.68. In looking at volatility levels, the shares saw weekly volatility of 3.34% and 2.67% over the past month.

Leave a Comment